We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Relationship Between Thoracic Aortic Structure Assessed B PET/CT Scan and Arterial Stiffness in Elderly Patients (FICTEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01963221
Recruitment Status : Completed
First Posted : October 16, 2013
Last Update Posted : October 16, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:

The purpose of this study is to determine the relationship between thoracic aortic inflammation and arterial stiffness in elderly patients.

Vascular-aging is accompanied by a gradual remodeling affecting both cardiac and arterial walls. Arterial hypertension, an established cardiovascular risk factor, has been suggested to exert pro-inflammatory actions threw several biological mediators enhancing arterial stiffness. Both effects of aging and hypertension are associated with higher levels of arterial stiffness, but their respective role is not well established in the pathophysiology of arterial stiffening.

Few data are available neither on the real anatomic aortic impact of aging and hypertension on aortic compliance and ventricular function and its relationship to arterial stiffness assessed by carotid-femoral pulse wave velocity, nor on the reliability of cine phase contrast magnetic resonance imaging arterial stiffness measurements.

Recent studies using positron emission tomography imaging (PET) with 18 F fluorodeoxyglucose (FDG) has been advocated as a means of measuring arterial wall inflammation in various population referred for oncology staging. FDG uptake is correlated with the number of cardiovascular risk factors and even the risk of future cardiovascular events. This method, combined with X-ray computed tomography (CT), has also demonstrated that aortic calcifications quantified by CT and local signs of inflammation detected by FDG uptake contribute to arterial stiffness. A strong relationship between large vessels stiffening assessed by carotid-femoral pulse wave velocity measurement, aortic calcifications quantified by CT and inflammation evaluated by FDG uptake has been demonstrated.

Therefore, in the current study, we use FDG PET associated to CT to characterize aortic inflammation and aortic calcifications coupled to pulse wave velocity measurement and cardiac function in elderly individuals.

In fact, if vascular aging promoting a local inflammatory process is a risk factor for cardiovascular disease, then vascular changes assessed by non-invasive vascular imaging (MRI,FDG PET) could represent a potential target for treatment and prevention Thirty individuals ≥ 65 years of age were examined, 15 hypertensive subjects and 15 controls. Pulse wave velocity, a surrogate for aortic stiffness, was measured both by cine phase contrast magnetic resonance imaging and applanation tonometry. Brachial pulse pressure, carotid calculated pulse pressure and pulse pressure amplification (brachial to carotid ratio), predictors of cardiovascular mortality were also quantified. Thoracic aorta local inflammation and calcification were measured by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Moreover, biomarkers of low grade inflammation (high-sensitivity C-reactive protein, interleukin 6 were also determined).

Condition or disease Intervention/treatment
Aging Inflammation Radiation: fludeoxyglucose(18f) Other: blood sample Other: cardiac and aortic magnetic resonance imaging Other: carotid femoral pulse wave velocity Radiation: positron emission tomography Radiation: computed tomography

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Study Start Date : January 2010
Primary Completion Date : August 2011
Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: CT Scans
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
fluodeoxyglucose (18f) Radiation: fludeoxyglucose(18f)
Other Names:
  • GLUSCAN, solution for injection
  • 600 MBq/ml : 564 461-8
Other: blood sample Other: cardiac and aortic magnetic resonance imaging Other: carotid femoral pulse wave velocity Radiation: positron emission tomography Radiation: computed tomography

Outcome Measures

Primary Outcome Measures :
  1. Aortic inflammation assessed by 18 F FDG maximal standard uptake value measurement [ Time Frame: one year ]

    Combined FDG PET/CT imaging was performed using a hybrid scanner hybrid system. For analysis, the thoracic aorta was divided into three segments: the ascending aorta, the aortic arch and the descending aorta. The standard uptake value (SUV) was calculated by dividing the activity measured in each voxel by the total injected activity, which was expressed per g of body weight and corrected for radioactive decay. Aortic activity was quantified using a conventional method on consecutive slices, which were orientated perpendicular to the aorta like described in previous publication. Region of interest (ROI) were drawn around the aorta on each trans-axial slice, allowing mean (SUVmean) and maximal aortic SUV (SUVmax) to be determined on every slice. These values were averaged to determine SUVmean and SUVmax for the ascending aorta, the aortic arch and the descending aorta.

    All PET scans were analyzed independently by two trained observers (VR, PM).

Secondary Outcome Measures :
  1. parietal thoracic aorta volume of calcification measured by computed tomography [ Time Frame: one year ]
    Volumes of aortic calcifications (VCa) were also determined for the three predetermined segments of thoracic aorta using a dedicated software and a threshold of 130 Hounsfield Unity. All scans were analyzed independently by two trained observers (VR, PM).

Other Outcome Measures:
  1. carotid femoral pulse wave velocity [ Time Frame: at the time of the measurement ]

    For carotid femoral pulse wave velocities determinations, measurements were done with a well-validated device. Aortic pulse wave velocity was measured at a central level, between carotid and femoral sites.

    The carotid femoral pulse wave velocity value was obtained by dividing the corresponding arterial length between two arterial sites by the time separating the onset of the pulse waves. Time intervals were determined by subtracting the delays, which were measured at each site between the R waves of ECG and the onset of the pulse waves and while averaging results from ten consecutive beats. Arterial length was defined as the distance from the suprasternal notch to the femoral radial minus the distance from the carotid artery to the suprasternal notch. Central systolic, diastolic and mean arterial pressures were estimated by recording the carotid pulse wave velocity.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age >=65 years old

Exclusion Criteria:

  • blood glucose> 200 mg/dl before the PET/CT scanning
  • inflammatory disease
  • cancer
  • all forms of secondary hypertension
  • renal hepatic or pulmonary insufficiency
  • absence of cardiac sinus rhythm
  • diabetes mellitus
  • contraindication to MRI
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01963221

University Hospital of Nancy
Vandoeuvre-les-Nancy, France, 54511
Sponsors and Collaborators
Central Hospital, Nancy, France
French Cardiology Society
Principal Investigator: Laure JOLY, MD, PhD Institut National de la Santé Et de la Recherche Médicale, France
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Laure JOLY, MCU-PH, MD, PhD, Central Hospital, Nancy, France
ClinicalTrials.gov Identifier: NCT01963221     History of Changes
Other Study ID Numbers: CentralHNF
First Posted: October 16, 2013    Key Record Dates
Last Update Posted: October 16, 2013
Last Verified: October 2013

Keywords provided by Laure JOLY, Central Hospital, Nancy, France:
arterial stiffness
PET/CT Imaging

Additional relevant MeSH terms:
Pathologic Processes
Fluorodeoxyglucose F18
Molecular Mechanisms of Pharmacological Action